Nanocarriers are promising tools for targeted and stimulus-responsive delivery of drugs to brain cancers, overcoming challenges like the blood-brain barrier (BBB). Brain cancers, particularly glioblastoma multiforme (GBM), have poor prognosis due to limited treatment options. Current therapies include surgery, radiation, and chemotherapy, but these often fail due to BBB limitations and side effects. Nanomedicine offers a solution by enabling precise drug delivery, improving BBB crossing, and targeting cancer cells. Stimulus-responsive nanocarriers can release drugs in response to external stimuli (e.g., magnetic fields, ultrasound) or internal cues (e.g., pH, enzymes, hypoxia), enhancing treatment efficacy and reducing toxicity. This review discusses the latest advances in nanomedicine for brain cancer treatment, focusing on targeted and stimulus-responsive nanocarriers. It covers various nanocarrier types, including polymeric, lipid-based, and inorganic systems, each with unique properties for drug delivery. Polymeric nanocarriers, such as block copolymer micelles and polymersomes, offer controlled release and targeting. Lipid-based systems, like liposomes and solid lipid nanoparticles, are effective for delivering drugs across the BBB. Inorganic systems, including gold nanoparticles, quantum dots, and magnetic nanoparticles, provide unique optical and magnetic properties for imaging and therapy. These nanocarriers can be functionalized with targeting ligands to enhance BBB crossing and tumor specificity. Stimulus-responsive systems, such as pH-sensitive or temperature-sensitive nanocarriers, allow for controlled drug release in the tumor microenvironment. The review highlights the potential of these nanocarriers for clinical translation, emphasizing their ability to improve treatment outcomes for brain cancers. Despite progress, challenges remain, including BBB permeability, toxicity, and scalability. Future research aims to optimize these systems for more effective and personalized brain cancer therapies.Nanocarriers are promising tools for targeted and stimulus-responsive delivery of drugs to brain cancers, overcoming challenges like the blood-brain barrier (BBB). Brain cancers, particularly glioblastoma multiforme (GBM), have poor prognosis due to limited treatment options. Current therapies include surgery, radiation, and chemotherapy, but these often fail due to BBB limitations and side effects. Nanomedicine offers a solution by enabling precise drug delivery, improving BBB crossing, and targeting cancer cells. Stimulus-responsive nanocarriers can release drugs in response to external stimuli (e.g., magnetic fields, ultrasound) or internal cues (e.g., pH, enzymes, hypoxia), enhancing treatment efficacy and reducing toxicity. This review discusses the latest advances in nanomedicine for brain cancer treatment, focusing on targeted and stimulus-responsive nanocarriers. It covers various nanocarrier types, including polymeric, lipid-based, and inorganic systems, each with unique properties for drug delivery. Polymeric nanocarriers, such as block copolymer micelles and polymersomes, offer controlled release and targeting. Lipid-based systems, like liposomes and solid lipid nanoparticles, are effective for delivering drugs across the BBB. Inorganic systems, including gold nanoparticles, quantum dots, and magnetic nanoparticles, provide unique optical and magnetic properties for imaging and therapy. These nanocarriers can be functionalized with targeting ligands to enhance BBB crossing and tumor specificity. Stimulus-responsive systems, such as pH-sensitive or temperature-sensitive nanocarriers, allow for controlled drug release in the tumor microenvironment. The review highlights the potential of these nanocarriers for clinical translation, emphasizing their ability to improve treatment outcomes for brain cancers. Despite progress, challenges remain, including BBB permeability, toxicity, and scalability. Future research aims to optimize these systems for more effective and personalized brain cancer therapies.